Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Endocrinology | Family Medicine
Disease Category: Diabetes Mellitus, Type 2
Location: United States, MO
A 16-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to compare the safety and efficacy of Starlix (nateglinide) vs. placebo in patients with type 2 diabetes who are inadequately controlled with basal insulin glargine in combination with metformin and/or thiazolidinedione (pioglitazone or rosiglitazone)
This study is for male and female patients with type 2 diabetes
that is not being controlled with regular diabetes medication.
Researchers want to find out if a drug called Starlix can help
people who are already taking glargin and metformin and/or
thiazolidinedione for their type 2 diabetes.
Patient Inclusion Criteria
- Patients must be between 18-78 years of age.
- Patients must have type 2 diabetes, being treated with insulin
glargine, metformin and/or thiazolidinedione (TZD).
- Patients must have HbA1C between 7 and 8.5 at
Patient Exclusion Criteria
- Patients must not of had any treatment with any anti-diabetic
medication other than glargine, metformin and/or thiazolidinedione
(TZD) in the past 3 months.
- Patients must not have Congestive heart failure requiring
- Patients must not of had a heart attack, coronary artery
surgery, or stroke in the past 6 months.
- Patients must not have any liver disease.
For more information,
Dynamic Clinical Research, Inc.
1010 Carondelet Drive, Suite 130
Kansas City, MO 64114
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these